Pfizer
Pfizer names leadership team post-Allergan merger
February 9, 2016Manufacturing and Production, Sales and Marketing Allergan, Pfizer
Pfizer has announced the executive leadership team for the combined Pfizer and Allergan business once the $160 billiion merger deal …
Pfizer revenues down, but above expectations
February 3, 2016Research and Development, Sales and Marketing Ian Read, Pfizer, financial results, income, profits, revenue, sales
Pfizer’s revenues took a hit from generic competition on former blockbusters, but the world’s new largest drugmaker still managed to …
UK Pfizer boss criticised for NHS conflict of interest
January 21, 2016Erik Nordkamp, Keep Our NHS Public, King's College Hospitals NHS Trsut, NHS, Pfizer, conflict of interest, privitisation
Anti-privatisation campaigners have called on a London NHS hospital trust to revoke its decision to appoint the head of Pfizer …
Pfizer may sell off Hospira unit for $2 billion
January 14, 2016Manufacturing and Production, Medical Communications, Sales and Marketing Hospira, Pfizer, injectables, pumps
Pfizer is reportedly considering selling Hospira’s infusion pump business for around $2 billion, having acquired the injectable drugs and infusion …
Baxalta’s Enbrel biosimilar measures up in late-stage study
January 13, 2016Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis
Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …
Pfizer raised 100 US drug prices 1 January
January 12, 2016Manufacturing and Production, Sales and Marketing Allergan, Drug pricing, Lyrica, Pfizer, ibrance, tax inversion
Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January, in …
Pfizer, Merck and Syndax in ovarian cancer trial collaboration
January 5, 2016Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer
Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …
Merck and Pfizer kick off Phase III avelumab cancer trials
December 23, 2015Research and Development Merck, Pfizer, avelumab, ovarian cancer
Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
Two new corporate affairs leads appointed at Pfizer
December 9, 2015Medical Communications Pfizer, corporate affairs
Pfizer has appointed MacKay Jimeson and Niesha Foster as corporate affairs leads. The company recently restructured its global pharma business …
Five benefits and challenges of the Pfizer/Allergan mega-merger
December 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Pfizer, acquisitions, mergers, takeovers
Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …
Pfizer to close UK R&D site in surprise move
December 4, 2015Research and Development, Sales and Marketing Pfizer
Two weeks after its $160 billion buyout of botox-maker Allergan, Pfizer has announced that it is to close a UK …
Pfizer lung cancer treatment gets expanded EU approval
December 1, 2015Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer
Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …
Pfizer hires new lead for gene therapy research centre
November 26, 2015Medical Communications, Research and Development Pfizer
Pfizer has hired Professor Michael Linden to lead its new gene therapy research centre in London. Professor Michael Linden has …
Trump and Clinton hit out at Pfizer over tax inversion plan
November 25, 2015Sales and Marketing Allergan, Pfizer
Politicians on both sides of the US spectrum have criticised Pfizer over its $160 billion buyout of Allergan and its …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
